Health Enhancement Products Announces Appointment of Ex-White House Chief of Staff, Hamilton Jordan, to Its Scientific Advisory Board; Jordan to Also Act as a Consultant to the Company

Business Wire, Dec 6, 2005

SCOTTSDALE, Ariz. -- Health Enhancement Products (OTCBB: HEPI) today announced that Hamilton Jordan has joined its scientific advisory board and become a consultant to the company. Jordan began his career as the youngest White House chief of staff under President Jimmy Carter. He has an extensive background in startup companies, particularly in the medical and biotech sectors. He was given an honorary Ph.D. by the Medical School of Georgia in 2004. He raised $30 million for Medcast, which was sold to WebMD for $200 million in 1998. He is an investor and director in a number of startup companies in the medical area, largely focused on cancer treatment. Two of those companies -- CTI Molecular Imaging and Proxima Therapeutics -- were sold this year. CTI Molecular Imaging was sold to Siemens for $1 billion and Proxima was sold to CYTYC for $200 million. He received the Public Service Award by the American Association of Cancer Researchers in 2002. Jordan has been a private consultant, providing strategic and communications advice to national and International companies such as Nike (NYSE: NKE), Coca Cola (NYSE: KO) and Wal-Mart (NYSE: WMT).

Jordan is the founder of the $1 billion Georgia Cancer Coalition. He's on the board of trustees of the American Association of Cancer Researchers Foundation and has been appointed to the National Dialogue on Cancer by President Bush. He's also on the board of directors of the Lance Armstrong Foundation and he's vice chairman of the Van Andel Cancer Institute. Jordan himself is the survivor of four different cancers.

Jordan said, "I have been closely following HEPI for over a year and believe its core science is strong and has great potential to help people with a variety of ailments. I am proud to be joining its scientific advisory board as a layman and working with some of the great people they have recruited."

Howard R. Baer, chairman and founder of Health Enhancement Products, stated, "I am humbled and honored to have someone as distinguished as Mr. Jordan feel that our company is worthy of his time. Mr. Jordan brings HEPI the invaluable experience of dealing with both government and corporate America, and in bringing products like ours to market. We feel that our product ProAlgaZyme has some potentially exciting new applications, and that Mr. Jordan could be instrumental in helping us move the product in the direction of such applications."

About Health Enhancement Products Inc.

Health Enhancement Products Inc. is a nutraceutical company engaged in the development of a supplementary health-enhancing product using only pure, all-natural ingredients. The company's sole product is ProAlgaZyme, a phytopercolate that is produced from an algae grown in 100% distilled water.

In September 2005, Health Enhancement Products Inc. filed a further patent application with the U.S. Patent and Trademark Office, relating to various methods of treatment using its phyto-percolate, ProAlgaZyme. This patent filing is directed to the treatment of a variety of diseases including cancer, cardiovascular disease and diseases related to immune system deficient disorders. The patent filing is also directed to methods of treatment for weight loss, inflammatory disorders responsive to COX-2 inhibition and glucose control. The patent application is for a method of treating or preventing a disease or disorder in a human by ingesting a phyto-percolate, which is derived from mixtures including freshwater algae, in this case being ProAlgaZyme. There are several treatment aspects of this patent application, which are supported by clinical data, including methods of treating immune system deficiency, type I and II diabetes, diseases related to the heart, cancer, arthritis and most other diseases related to a deficient immune system.

The algae from which ProAlgaZyme is derived produces a protein, most likely as a means of protecting itself from exposure to outside disease and harmful bacteria. The protein solution is then drawn off, filtered, tested and bottled for consumption. In addition to supporting a compromised immune system, recent clinical studies indicate that ProAlgaZyme has potential weight loss properties. ProAlgaZyme has also been shown in a clinical study to have the potential to improve serum glucose management, when combined with a diet low in refined carbohydrates and a light exercise regimen.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to fund its operations and market and sell its ProAlgaZyme product. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.